ClinicalTrials.gg
CompletedNCT02574663Updated Oct 2, 2019

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

A Phase 1 interventional study of TGR-1202 and nab-paclitaxel + gemcitabine in Pancreatic Cancer, Colorectal Cancer and Rectal Cancer, sponsored by TG Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-02.

Sponsored by TG Therapeutics, Inc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,850 studies in Pancreatic Neoplasms with a site in United States — 297 open to participants now, 469 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.

Enrollment
480th of 1,573
66 · median 37
Started
2015
with 73 others
Phase 1
555 of 1,850
74 open now
Registered
911th of 1,850
by date

Among the 1,850 studies in Pancreatic Neoplasms with a site in United States, this one is the 480th largest by enrollment of the 1,573 interventional ones that give a count, is one of 74 that started in 2015, is one of 555 in phase 1, and was the 911th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

297 of the 1,850 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

292 more — sign in →

All 297 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,850 studies in Pancreatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1 multi-center study to assess the safety and efficacy of TGR-1202 as a single agent or in combination with nab-paclitaxel + gemcitabine or with FOLFOX in patients with select relapsed or refractory solid tumors.

Read the detailed description

TGR-1202 will be evaluated alone or in combination with nab-paclitaxel + gemcitabine or with FOLFOX in patients with adenocarcinoma of the pancreas, adenocarcinoma of the colon, rectum, gastric and GE junction cancer, and GI Stromal Tumor (GIST) who have relapsed from or are refractory to prior treatment.

03

Conditions studied

  • Pancreatic Cancer
  • Colorectal Cancer
  • Rectal Cancer
  • Gastric Cancer
  • Esophageal Cancer
  • Gastrointestinal Stromal Tumor (GIST)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed:

    1. adenocarcinoma of the pancreas (pancreatic cancer)
    2. adenocarcinoma of the colon or rectum (colorectal cancer)
    3. adenocarcinoma of the gastric (gastric cancer)
    4. esophageal cancer
    5. gastrointestinal stromal tumor (GIST)
  • disease
  • by 1.1

Exclusion criteria

Exclusion Criteria:

  • Known , C or infection
  • Previous therapy with any drug that inhibits the PI3K pathway
  • Anti-tumor therapy within 21 days of study Day 1
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    TGR-1202

    TGR-1202 daily dose

    Drug: TGR-1202

  • Experimental
    TGR-1202 + nab-paclitaxel + gemcitabine

    TGR-1202 oral daily dose + nab-paclitaxel + gemcitabine both as an IV infusion

    Drug: TGR-1202 · Drug: nab-paclitaxel + gemcitabine

  • Experimental
    TGR-1202 + FOLFOX

    TGR-1202 oral daily dose + oxaliplatin IV infusion + leucovorin IV infusion followed by 5-fluorouracil IV bolus followed by 5-FU IV infusion (FOLFOX regimen)

    Drug: TGR-1202 · Drug: Oxaliplatin + Folinic acid + Fluorouracil

  • Experimental
    TGR-1202 + FOLFOX + Bevacizumab

    TGR-1202 oral daily dose + oxaliplatin IV infusion + leucovorin IV infusion followed by 5-fluorouracil IV bolus followed by 5-FU IV infusion (FOLFOX regimen) + bevacizumab IV infusion

    Drug: TGR-1202 · Drug: Oxaliplatin + Folinic acid + Fluorouracil + Bevacizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse events as a measure of safety and tolerability of TGR-1202 as a single agent and in combination in combination with nab-paclitaxel + gemcitabine, or with oxaliplatin + leucovorin + 5-FU (FOLFOX) or with FOLFOX + bevacizumab.

    To determine the incidence of adverse events, any potential abnormal laboratory results and any dose-limiting toxicities.

    Time frame: Up to 28 days after the last patient enrolled

Secondary outcomes

  1. Overall Response Rate

    Overall response rate with TGR-1202 as a single agent and in combination with nab-paclitaxel + gemcitabine, or with oxaliplatin + leucovorin + 5-FU (FOLFOX) or with FOLFOX + bevacizumab.

    Time frame: Up to 1 year

  2. Duration of Response

    Duration of response with TGR-1202 as a single agent and in combination with nab-paclitaxel + gemcitabine, or with oxaliplatin + leucovorin + 5-FU (FOLFOX) or with FOLFOX + bevacizumab.

    Time frame: Up to 1 year

  3. Pharmacokinetic (PK) profile of TGR-1202. Peak Plasma Concentration (Cmax).

    This endpoint will measure the plasma PK profile of TGR-1202 as a single agent and in combination with nab-paclitaxel + gemcitabine, or with oxaliplatin + leucovorin + 5-FU (FOLFOX) or with FOLFOX + bevacizumab.

    Time frame: At selected timepoints up through 6 months

  4. Pharmacokinetic (PK) profile of TGR-1202. Time to Peak Plasma Concentration (Tmax).

    Time frame: At selected timepoints up through 6 months

  5. Pharmacokinetic (PK) profile of TGR-1202. Area under the plasma concentration versus time curve (AUC)

    Time frame: At selected timepoints up through 6 months

07

Study locations

1 site
  • TG Therapeutics Trial Site
    Nashville, Tennessee 37203, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Aug 2018, 35 months.

Of 171 industry-sponsored phase 1 interventional studies under Pancreatic Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 62. This study's 35 months is below that.

Counting every sponsor, half of 380 studies reached it within 45 months; a quarter within 32 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2015
First posted
Oct 14, 2015
StartActual
Sep 11, 2015
Primary completionActual
Aug 2018
CompletionActual
Aug 2018
Last update
Oct 2, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02574663
Responsible party
Sponsor
First posted
Oct 14, 2015
Start date
Sep 11, 2015
Primary completion
Aug 2018
Completion
Aug 2018
Last update
Oct 2, 2019

Study contacts

Johanna Bendell, MD
study chair · Sarah Cannon Research Instititue (SCRI)

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Umbralisib

Start the discussion